Drug Profile
Millamolecule - Bristol-Myers Squibb/PeptiDream
Alternative Names: PD-L1 inhibitor millamolecule; PD-L1 inhibitor millamolecule - Bristol-Myers SquibbLatest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb; PeptiDream
- Developer Bristol-Myers Squibb
- Class Macrocyclic compounds; Peptides
- Mechanism of Action Programmed cell death-1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Immunological disorders